The Checkpoint Immunotherapy Revolution: What Started as a Trickle Has Become a Flood, Despite Some Daunting Adverse Effects; New Drugs, Indications, and Combinations Continue to Emerge.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  P & T : a peer-reviewed journal for formulary management

• Publication date

  2016-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 26957887PMCID PMC4771089
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

  2016cited by this paper
• A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

  2016cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Society for melanoma research and american heart association scientific sessions.

  2015cited by this paper
• Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL).

  2015cited by this paper
• PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.

  2015cited by this paper
• Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

  2014cited by this paper
• 1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA.

  2014cited by this paper
• Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.

  2014cited by this paper
• Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions.

  2014cited by this paper
• Phase I study of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma (mRCC).

  2014cited by this paper
• Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

  2014cited by this paper
• OX40 is a potent immune-stimulating target in late-stage cancer patients.

  2013cited by this paper
• Abstract 1248: Intralesional injection with PV-10 induces a systemic anti-tumor immune response in murine models of breast cancer and melanoma.

  2013cited by this paper
• FDA approves new treatment for a type of late-stage lung cancer

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper

• Safety and Efficacy of Atezolizumab in Combination With nab-Paclitaxel in Patients With PD-L1 Positive Metastatic or Locally Advanced Triple-Negative Breast Cancer: A UK-Wide Cancer Centre Experience.

  2025cites this paper
• Advanced biomaterials and delivery modalities to alleviate cancer therapy-induced inflammation.

  2025cites this paper
• A new era in melanoma immunotherapy: focus on DCs metabolic reprogramming

  2025cites this paper
• The Safety and Efficacy of Immune Checkpoint Blockade in Children, Adolescents, and Young Adults: A Systematic Review and Meta-Analysis

  2025cites this paper
• Barriers to T Cell Functionality in the Glioblastoma Microenvironment

  2024cites this paper
• Co-Occurring Infections in Cancer Patients Treated with Checkpoint Inhibitors Significantly Increase the Risk of Immune-Related Adverse Events

  2024cites this paper
• Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review

  2024cites this paper
• Design, synthesis, pharmacological evaluation, and computational study of benzo[d] isothiazol-based small molecule inhibitors targeting PD-1/PD-l1 interaction.

  2024cites this paper
• Patient reported outcomes and patient experiences of immune checkpoint modulators for advanced or recurrent melanoma: a mixed methods study

  2024cites this paper
• Increasing melanoma incidence with unchanged mortality: more sunshine, better treatment, increased diagnostic activity, overdiagnosis or lowered diagnostic threshold?

  2024cites this paper
• VDX‐111, a novel small molecule, induces necroptosis to inhibit ovarian cancer progression

  2024cites this paper
• Redefining the battle against colorectal cancer: a comprehensive review of emerging immunotherapies and their clinical efficacy

  2024cites this paper
• Co-occurring infections in cancer patients treated with checkpoint inhibitors significantly increase the risk of immune related adverse events

  2024cites this paper
• Treatment patterns and outcomes of high-grade immune checkpoint inhibitor-related pneumonitis in an oncology hospitalist service

  2024cites this paper
• Case report: Long-term response to a combination of immune checkpoint inhibitors as a single treatment for multiple synchronous cancers: a case study

  2024cites this paper
• Myositis associated with pembrolizumab presenting with myastheniform symptoms: two case reports

  2024cites this paper
• Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy

  2024cites this paper
• Applying single‐cell highly multiplexed secretome proteomics to characterize immunotherapeutic products and predict clinical responses

  2023cites this paper
• CDK4/6 inhibition sensitizes intracranial tumors to PD-1 blockade in preclinical models of brain metastasis.

  2023cites this paper
• Exploring BenzylethoxyAryl Urea Scaffolds for Multitarget Immunomodulation Therapies

  2023cites this paper
• Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.

  2023cites this paper
• Vitreous metastasis from cutaneous melanoma: diagnosis and management

  2023cites this paper
• Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients

  2023cites this paper
• Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events

  2022cites this paper
• mRNA-Based Approaches to Treating Liver Diseases

  2022cites this paper
• Interval design to identify the optimal biological dose for immunotherapy

  2022cites this paper
• Phagocytosis-Regulators-Based Signature to Predict the Prognosis and Chemotherapy Resistance for Breast Cancer Patients

  2022cites this paper
• The role of kidney biopsy in immune checkpoint inhibitor nephrotoxicity

  2022cites this paper
• Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

  2022cites this paper
• Immune checkpoint inhibitor toxicity and associated outcomes in older patients with cancer.

  2022cites this paper
• Gene-Immune Therapy of Cancer: Approaches and Problems

  2022cites this paper
• Immune-related aseptic meningitis and strategies to manage immune checkpoint inhibitor therapy: a systematic review

  2022cites this paper
• Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.

  2022cites this paper
• Correction to: Multiscale imaging of therapeutic anti-PD-L1 antibody localization using molecularly defined imaging agents Iris

  2022cites this paper
• Nature and Significance of Stromal Differentiation,, PD-L1, and VISTA in GIST.

  2021cites this paper
• Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma

  2021cites this paper
• Human disease clinical treatment network for the elderly: The analysis of medicare inpatient length of stay data

  2021cites this paper
• HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression

  2021cites this paper
• Efficacy and safety of immune checkpoint inhibitors in patients with non‐small cell lung cancer aged 80 years or older

  2021cites this paper
• Nature and Significance of Stromal Differentiation, PD-L1, and VISTA in GIST: Shifting Current Paradigms

  2021influential citation
• Injectable Nanoparticle‐Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies

  2021cites this paper
• Anti-tumor effects of RTX-240: an engineered red blood cell expressing 4-1BB ligand and interleukin-15

  2021cites this paper
• Combining nanomedicine and immune checkpoint therapy for cancer immunotherapy.

  2021cites this paper
• Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature

  2021cites this paper
• Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data

  2021cites this paper
• ACT Up TIL Now: The Evolution of Tumor-Infiltrating Lymphocytes in Adoptive Cell Therapy for the Treatment of Solid Tumors

  2021cites this paper
• Plant Viral Nanoparticle Conjugated with Anti-PD-1 Peptide for Ovarian Cancer Immunotherapy

  2021cites this paper
• Epidemiology of Melanoma

  2021cites this paper
• Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy

  2021cites this paper
• Comparison of Anticancer Drug Toxicities: Paradigm Shift in Adverse Effect Profile

  2021cites this paper
• Interferons: role in cancer therapy.

  2020cites this paper
• The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

  2020cites this paper
• Innate Immune Cells and Their Contribution to T-Cell-Based Immunotherapy

  2020cites this paper
• Rituximab for Immune Checkpoint Inhibitor Myasthenia Gravis

  2020cites this paper
• Cancer-Associated Fibroblast Mediated Inhibition of CD8+ Cytotoxic T Cell Accumulation in Tumours: Mechanisms and Therapeutic Opportunities

  2020cites this paper
• Evaluation of the Reporting of Safety and Immune-Related Adverse Events in Clinical Trials of FDA-Approved Immune Checkpoint Inhibitors in Oncology

  2020cites this paper
• Design, Synthesis and Biological Evaluation of Novel 1,2,5-Oxadiazol-3-Carboximidamide Derivatives as Indoleamine 2, 3-Dioxygenase 1 (IDO1) Inhibitors.

  2020cites this paper
• Peptide-based targeting of immunosuppressive cells in cancer

  2020cites this paper
• Personalized Medicine - Dream or Reality?

  2019cites this paper
• Simplified Admix Archaeal Glycolipid Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Enhances Protection from Murine Melanoma

  2019cites this paper
• Circadian Rhythms and Personalized Melanoma Therapy

  2019cites this paper
• In situ vaccination: Harvesting low hanging fruit on the cancer immunotherapy tree.

  2019cites this paper
• Introduction to the Immune System.

  2019cites this paper
• Nivolumab in patients with advanced hepatocellular carcinoma and Child‐Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series

  2019cites this paper
• Enforcing the checkpoints: harnessing T-cell exhaustion for therapy of T1D

  2019cites this paper
• Epigenetic alterations are associated with tumor mutation burden in non-small cell lung cancer

  2019cites this paper
• Immune regulation of metastasis: mechanistic insights and therapeutic opportunities

  2018cites this paper
• Missed Druggable Cancer Hallmark: Cancer–Stroma Symbiotic Crosstalk as Paradigm and Hypothesis for Cancer Therapy

  2018cites this paper
• Recent advances in small molecule based cancer immunotherapy.

  2018cites this paper
• Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.

  2018cites this paper
• Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology

  2018cites this paper
• Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2

  2018cites this paper
• Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review

  2018influential citation
• Delivering Type I Interferon to Dendritic Cells Empowers Tumor Eradication and Immune Combination Treatments.

  2018cites this paper
• Oncolytic Viruses as Antigen-Agnostic Cancer Vaccines.

  2018cites this paper
• Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.

  2018cites this paper
• The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies

  2018cites this paper
• Checks and Balances in Autoimmune Vasculitis

  2018cites this paper
• University of Groningen Checks and Balances in Autoimmune Vasculitis

  2018cites this paper
• Cancer–stroma interactions as a target for cancer treatment.

  2018cites this paper
• CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors

  2018cites this paper
• Oncolytic Viruses as Antigen Agnostic Tumor Vaccines

  2018cites this paper
• iMALDI as a tool to improve patient stratification for targeted cancer therapies

  2018cites this paper
• Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes

  2018cites this paper
• Emerging Potential of Cancer Therapy—Binary Direct Interactions of Cancer and Stromal Cells

  2018cites this paper
• Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy.

  2018cites this paper
• An Overview of Immune Checkpoints and Immunotherapy in Cancer

  2018cites this paper
• Activation of phagocytosis by immune checkpoint blockade

  2018cites this paper
• Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers

  2018cites this paper
• Treating melanoma in an experimental system by targeting glutamatergic signaling and PD-1 inhibition

  2017influential citation
• The Ageing Immune System and Health

  2017cites this paper
• Memory Potential, Molecular Characterization, and Translational Applications of the Novel ThEO/TcEO T Cell Phenotype

  2017cites this paper
• Modifying the Fc Asn297 Glycan of Human IgG2 Subclass for Improved Antibody Therapeutics and Design of Site-Specific Antibody Drug Conjugates

  2017cites this paper
• Cancer Genomics in the Era of Checkpoint Inhibition: Biomarkers to Predict Tumor Response to Checkpoint Inhibition Therapy

  2017cites this paper
• Autophagic Mechanism in Anti-Cancer Immunity: Its Pros and Cons for Cancer Therapy

  2017cites this paper
• Anti–Programmed Cell Death 1/Ligand 1 (PD‐1/PD‐L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development

  2017cites this paper
• Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research‐practice gaps, challenges, and insights

  2017cites this paper
• Immuno-Oncology—The Translational Runway for Gene Therapy: Gene Therapeutics to Address Multiple Immune Targets

  2017cites this paper
• The current status of immunobased therapies for metastatic renal-cell carcinoma

  2017cites this paper
• Metallic Nanoparticles for Cancer Immunotherapy.

  2017cites this paper